<DOC>
	<DOCNO>NCT02483169</DOCNO>
	<brief_summary>Through study , investigator prove Cilostazol effectively prevent progression intima-medial thickness ischemic stroke patient high risk cerebral hemorrhage , along significant increase risk occurrence hemorrhagic side effect . The primary hypothesis study ; Cilostazol alone probucol reduce progression intima-medial thickness compare aspirin ischemic stroke patient symptomatic asymptomatic old cerebral hemorrhage .</brief_summary>
	<brief_title>PreventIon IMT Progression iSchemic Stroke Patients With High Risk Cerebral HemOrrhage-IMT Study</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Intracranial Hemorrhages</mesh_term>
	<mesh_term>Brain Ischemia</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<mesh_term>Probucol</mesh_term>
	<criteria>Clinical diagnosis ischemic stroke within 120 day Adult age 20 year old High risk hemorrhagic stroke ( history intracranial hemorrhage image evidence previous intracranial hemorrhage ) Informed consent Clinical diagnosis myocardial infarction coronary intervention within 4 week Bleeding tendency Pregnant breastfeed woman Hemorrhagic stroke within 6 month Patient take antithrombotic medication aspirin agree change previous medication Severe cardiovascular disease cardiomyopathy congestive heart failure Life expectancy less one year Contraindication long term aspirin use Enrolled clinical trial within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>ischemic stroke</keyword>
	<keyword>intracranial hemorrhage</keyword>
	<keyword>cilostazol</keyword>
	<keyword>probucol</keyword>
	<keyword>intima medium thickness</keyword>
</DOC>